根据最新提交的SEC文件显示,InMed Pharmaceuticals Inc已明确其研发时间表,公司目标在2027年完成INM-901的新药临床试验申请(IND)提交工作,并同步启动该药物的第一阶段临床实验。这一规划标志着其在药物研发领域的又一重要布局。
根据最新提交的SEC文件显示,InMed Pharmaceuticals Inc已明确其研发时间表,公司目标在2027年完成INM-901的新药临床试验申请(IND)提交工作,并同步启动该药物的第一阶段临床实验。这一规划标志着其在药物研发领域的又一重要布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.